Benzinga · Aug 14, 2026
Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY
Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.35) per share. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year.
NASDAQ · BCLI
Brainstorm Cell Therapeutics Inc.
Healthcare · Biotechnology
$0.95
Up+$0.05 (+5.49%)
Updated Oct 10, 2026, 2:12 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.18M
- P/E ratio
- -0.57
- Dividend yield
- 0.00%
- 52-week range
- $0.46 – $1.92
- Volume
- 6.99K
- Avg. volume
- 18.54K
Price performance · BCLI
BCLI price history
1M range · 0 trading sessions · Daily adjusted prices
BCLI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BCLI news
The latest Smart Investors Daily articles mentioning BCLI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BCLI research
Overview
Company profile and research snapshot.
Company profile
BRAINSTORM CELL THERAPUTC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 23, 2025 | Maxim Group | Hold | — |
| Jul 11, 2024 | Maxim Group | Buy | — |
| Sep 28, 2023 | Maxim Group | Hold | — |
| Mar 31, 2023 | Maxim Group | Buy | — |
| Feb 5, 2021 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and
Benzinga · May 28, 2026
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director
BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of
Finnhub · May 15, 2026
Brainstorm Cell Therapeutics announces first quarter 2026 financial results and provides corporate update
Brainstorm Cell Therapeutics Inc:Brainstorm Cell Therapeutics announces first quarter 2026 financial results and provides corporate update....
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
